Form 4: Avalon Ventures Distributes Janux Therapeutics Shares In-Kind

Avalon Ventures XI, L.P. reports an in-kind distribution of Janux Therapeutics shares to its partners, resulting in changes in beneficial ownership.

Summary

• Avalon Ventures XI, L.P., along with related entities Avalon BioVentures SPV I, L.P. and Avalon BioVentures I, LP, filed a Form 4 regarding changes in beneficial ownership of Janux Therapeutics, Inc. (JANX) shares on February 29, 2024.
• The filing indicates a pro-rata, in-kind distribution of shares, not a purchase or sale, to the general partners and limited partners of Avalon Ventures XI, LP, Avalon BioVentures SPV I, LP, and Avalon BioVentures I, LP.
• These distributions resulted in changes in the amount of shares directly held by these entities and indirectly held by their general partners and members.
• Avalon Ventures XI, L.P. directly holds 3,948,495 shares of common stock after the distribution.
• Avalon BioVentures SPV I, LP directly holds 4,031,543 shares of common stock after the distribution.
• Avalon BioVentures I, LP directly holds 764,869 shares of common stock after the distribution.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an in-kind distribution of shares. It doesn't contain information that would significantly impact sentiment positively or negatively.

Industry Context

In-kind distributions are a common practice in the venture capital and private equity industries, allowing for the distribution of assets to limited partners without requiring a sale on the open market.

Stakeholder Impact

• The in-kind distribution may impact the holdings of the limited partners of Avalon Ventures XI, L.P., Avalon BioVentures SPV I, L.P., and Avalon BioVentures I, LP.

Key Dates